InflaRx presents kidney data for InflaRx stock investors

Published on 10/25/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Izicopan showed kidney potential in two hamster models on October 22, 2026. A 100 mg/kg dose and 14-day regimen frame InflaRx stock research.

Pipeline evidence and dates

InflaRx reported izicopan kidney data from two hamster models on October 22, 2026.
A 100 mg/kg dose reduced kidney injury markers in the ischemia-reperfusion model.
InflaRx is scheduled to report third-quarter results on November 9, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx N.V. (ISIN NL0012661870) presented new izicopan data from two hamster kidney-injury models on October 22, 2026. The release linked the findings to possible development in renal diseases and ANCA-associated vasculitis, while the stock had closed at USD 1.56 on Nasdaq on October 23, 2026.

Two models supply the evidence

According to GlobeNewswire, InflaRx evaluated izicopan in renal ischemia-reperfusion injury and unilateral ureteral obstruction models. In the first model, a single oral dose of 100 mg/kg reduced plasma creatinine and blood urea nitrogen versus vehicle, with both results carrying a p-value below 0.001.

The second model used daily dosing for 14 days. The release reported lower blood urea nitrogen and an improved histopathological score, each versus vehicle, with p-values below 0.001 and 0.05 respectively. The fibrosis assessment showed a numerical trend rather than a reported statistically significant result.

What does the pipeline data mean?

The evidence remains preclinical, so the immediate investment question is whether InflaRx can translate animal-model findings into clinical development. The October 22 release said the company is planning oral izicopan development in ANCA-associated vasculitis and additional renal indications.

The chronology is clear. On May 6, 2026, InflaRx announced pricing of a USD 150.0 million offering on its investor-relations page. On October 2, 2026, the company announced a late-breaking Kidney Week poster built around at least 90.00 percent C5a blockade over 14 days. On October 22, 2026, it presented data from two kidney models, according to GlobeNewswire.

Upcoming reporting date

The next explicitly scheduled company date is November 9, 2026, when InflaRx is expected to report third-quarter results, according to MarketBeat. That report may give investors a fresh measure of spending and liquidity alongside the clinical program updates.

Stock context after the data

InflaRx is a clinical-stage biotechnology company developing inhibitors that target the complement system. Its primary program is the oral C5a receptor inhibitor izicopan, while vilobelimab remains part of its anti-C5a pipeline.

On Nasdaq, InflaRx closed at USD 1.56 on October 23, 2026. The euro quote from Tradegate stood at EUR 1.41 on October 22, 2026 at 11:46 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.